Substance / Medication

Mequitazine

Overview

Active Ingredient
mequitazine
RxNorm CUI
29528

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol.
van der Sluiszen N N J J M, Vermeeren A, Jongen S et al. · Psychopharmacology (Berl) · 2016
PMID: 27488192RCTFull text (PMC)
Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance.
Theunissen Eef L, Vermeeren Annemiek, Ramaekers Johannes G · Br J Clin Pharmacol · 2006
PMID: 16390354RCTFull text (PMC)
Development of radioiodine-labeled mequitazine for evaluation of hepatic CYP2D activity.
Mizutani Asuka, Kobayashi Masato, Nishi Kodai et al. · Front Pharmacol · 2024
PMID: 38962307OtherFull text (PMC)
Asymmetric synthesis of (+)-mequitazine from quinine.
Leroux Sébastien, Larquetoux Laurent, Nicolas Marc et al. · Org Lett · 2011
PMID: 21657243Other
Expedient synthesis of mequitazine an antihistaminic drug by palladium catalyzed allylic alkylation of sodium phenothiazinate.
Gonnot Vanessa, Nicolas Marc, Mioskowski Charles et al. · Chem Pharm Bull (Tokyo) · 2009
PMID: 19881287Other
Photodegradation and photostability-indication of mequitazine.
Abdel-Moety Ezzat M, Ibrahim Mohamed A, Rezk Mamdouh R · Spectrochim Acta A Mol Biomol Spectrosc · 2009
PMID: 19729339Other
Pipette tip solid-phase extraction and gas chromatography-mass spectrometry for the determination of mequitazine in human plasma.
Kumazawa Takeshi, Hasegawa Chika, Lee Xiao-Pen et al. · Talanta · 2006
PMID: 18970795Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mequitazine (substance)
SNOMED CT
414674005
UMLS CUI
C0065972
RxNorm CUI
29528

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.